COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26 center dot 2%) had myeloid, 121 (51 center dot 1%) lymphoid and 54 (22 center dot 8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3 center dot 42; 95% confidence interval (CI), 1 center dot 04-11 center dot 21; P = 0 center dot 04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0 center dot 35; 95% CI: 0 center dot 11-1 center dot 13; P = 0 center dot 08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies / Passamonti, Francesco; Romano, Alessandra; Salvini, Marco; Merli, Francesco; Porta, Matteo G Della; Bruna, Riccardo; Coviello, Elisa; Romano, Ilaria; Cairoli, Roberto; Lemoli, Roberto; Farina, Francesca; Venditti, Adriano; Busca, Alessandro; Ladetto, Marco; Massaia, Massimo; Pinto, Antonio; Arcaini, Luca; Tafuri, Agostino; Marchesi, Francesco; Fracchiolla, Nicola; Bocchia, Monica; Armiento, Daniele; Candoni, Anna; Krampera, Mauro; Luppi, Mario; Cardinali, Valeria; Galimberti, Sara; Cattaneo, Chiara; La Barbera, Elettra Ortu; Mina, Roberto; Lanza, Francesco; Visani, Giuseppe; Musto, Pellegrino; Petrucci, Luigi; Zaja, Francesco; Grossi, Paolo A; Bertù, Lorenza; Pagano, Livio; Corradini, Paolo. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - ELETTRONICO. - 195:3(2021), pp. 371-377. [10.1111/bjh.17704]
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
Romano, Alessandra;Lemoli, Roberto;Farina, Francesca;Lanza, FrancescoMembro del Collaboration Group
;Corradini, Paolo
2021
Abstract
COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26 center dot 2%) had myeloid, 121 (51 center dot 1%) lymphoid and 54 (22 center dot 8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3 center dot 42; 95% confidence interval (CI), 1 center dot 04-11 center dot 21; P = 0 center dot 04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0 center dot 35; 95% CI: 0 center dot 11-1 center dot 13; P = 0 center dot 08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.File | Dimensione | Formato | |
---|---|---|---|
BJH-195-371.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF | Visualizza/Apri |
bjh17704-sup-0001-appendixs1.docx
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
181.79 MB
Formato
Microsoft Word XML
|
181.79 MB | Microsoft Word XML | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.